Botox Medical Market

The botox medical market was valued at USD 4,942.9 Mn by 2019. The rising prevalence of the aging process in the geriatric population worldwide increases the demand for facial aesthetics procedures. Additionally, the clinical application of botox in the treatment of cervical dystonia, overactive urinary bladder, severe axillary hyperhidrosis, etc. further propel the botox medical market growth.

Botulinum toxin A and B are prescription medicines which need to be administered under medical supervision on account of the severe drug-related adverse events such as headache, dysphagia, nausea, the spread of toxic effects, etc. The maximum cumulative dose must not exceed 400 units in a span of 3 months in adults receiving botulinum toxin A injections. The dose recommendation for botulinum toxin B in patients receiving between 12 to 16 weeks is 5000 units or 10,000 units.

The major segments related to the botox medical market are: 

By Product (2017–2027; US$ Mn)

Botulinum Toxin A

Botulinum Toxin B

By End Users (2017–2027; US$ Mn)

Hospitals

Dermatology Clinics

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global botox medical market
• The overall segmentation of the botox medical market, by product, end-users and geography are minutely studied. Botulinum toxin A and dermatology clinics are dominating the product and end-user segments respectively
• Increasing demand for facial aesthetics in the geriatric population worldwide
• A constant rise in the muscular spasm throughout the globe increases the demand for botulinum toxin B market

Report gist?

• The study of the global botox medical market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers a qualitative and quantitative analysis of the overall market segmented on the basis of product and end-users and categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the biopharmaceutical manufacturers actively engaged in the production and marketing of botox medical on account of the increasing demand for facial aesthetics in the geriatric population worldwide
• The report will benefit formulation scientist engaged in the development of botulinum toxin B products for the treatment of muscular spasm throughout the globe
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to botox medical market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Botulinum toxin A is representing the largest market share in the product segment for the botox medical market. A significant increase in the cosmetic aesthetics procedures conducted worldwide and a constant rise in the demand for facial aesthetics in the geriatric population throughout the globe together drives the market growth. It is basically a vacuum-dried purified toxin of type A obtained from the fermentation process of Clostridium botulinum type A strain. It is a 150 KDa neurotoxic protein that blocks neuromuscular transmission by binding to the acceptor sites of motor or the sympathetic nerve terminals. Botulinum toxin B is keen to register rampant market growth during the forecast period on account of its clinical application in the treatment of cervical dystonia and mitigate the intense pain associated with abnormal head and neck position.

Dermatology clinics are leading the end-user segment for the botox medical market. The availability of state of the art medical equipment and other facilities to conduct cosmetic aesthetics procedures is responsible for its popularity among consumers keen to undergo aesthetics treatment to reduce aging and enhance external facial appearance. Hospitals are expected to record steady market growth in the near future owing to the rising public health awareness in the benefit of botulinum toxin B for the treatment of muscular spasticity.

North America is spearheading the geography segment for the botox medical market. Increasing demand for facial aesthetics in the geriatric population primarily drives the market growth in the region. Availability of large disposable income and domicile of key players such as Allergan, Plc. (Abbvie, Inc.), Galderma S.A., US Worldmed LLC., Evolus, Inc. further accentuates the market growth in the region. Europe is placed in the second position in the regional segment for the botox medical market. The growing incidence of muscular spasticity increases the demand for botulinum toxin B market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment in the botox medical market. Rising public awareness regarding facial aesthetics and botox application in increasing skin elasticity and combating the aging process and constant growth in dermatology clinics together steer the botox medical market growth in the Asia Pacific region.